Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments

Maria Kyrgiou; Georgia Salanti; Nicholas Pavlidis; Evangelos Paraskevaidis; John P A Ioannidis

doi:10.1093/jnci/djj443

Back

Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments

Article 2006 en

Abstract

1 min read

Distinct incremental improvements in survival have been achieved for ovarian cancer chemotherapy over time, with the possibility to achieve a doubling or more of time to mortality with platinum and taxane combinations, especially when intraperitoneal administration is used.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2008

Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer

Davide Mauri, Nikolaos P. Polyzos, Georgia Salanti, Nicholas Pavlidis, John P A Ioannidis

Article2006

Current Treatment of Relapsed Ovarian Carcinoma

Aristotle Bamias, Alexandros Rodolakis, Meletios A Dimopoulos

Article2012

<i>BRCA1</i>epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer

Ólafur Andri Stefánsson, Alberto Villanueva, August Vidal, Lola Martí, Manel Esteller

Article2008

Prognostic value of kallikrein‐related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA)

Panteleimon Kountourakis, Amanda Psyrri, Andreas Scorilas, Robert L. Camp, Sonia Markakis, Diane Kowalski, Eleftherios P. Diamandis, Meletios A Dimopoulos

Article2009

Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis

Andreas Scorilas, Sonia Markakis, Diane Kowalski, Robert L. Camp, Eleftherios P. Diamandis, Meletios A Dimopoulos, Panteleimon Kountourakis, Amanda Psyrri